132 related articles for article (PubMed ID: 16830264)
41. Laronidase desensitization during stem cell transplant in a child with Hurler syndrome.
Rosenberg J; Jhaveri P; Kelbel T
Ann Allergy Asthma Immunol; 2016 Apr; 116(4):377-8. PubMed ID: 26916445
[No Abstract] [Full Text] [Related]
42. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome.
Grewal SS; Wynn R; Abdenur JE; Burton BK; Gharib M; Haase C; Hayashi RJ; Shenoy S; Sillence D; Tiller GE; Dudek ME; van Royen-Kerkhof A; Wraith JE; Woodard P; Young GA; Wulffraat N; Whitley CB; Peters C
Genet Med; 2005 Feb; 7(2):143-6. PubMed ID: 15714083
[TBL] [Abstract][Full Text] [Related]
43. Regression of ventriculomegaly following medical management of a patient with Hurler syndrome.
Liang J; Singhal A
J Neurosurg Pediatr; 2016 May; 17(5):537-9. PubMed ID: 26745646
[TBL] [Abstract][Full Text] [Related]
44. Carbon nanotubes as nanovectors for intracellular delivery of laronidase in Mucopolysaccharidosis type I.
Da Ros T; Ostric A; Andreola F; Filocamo M; Pietrogrande M; Corsolini F; Stroppiano M; Bruni S; Serafino A; Fiorito S
Nanoscale; 2018 Jan; 10(2):657-665. PubMed ID: 29239447
[TBL] [Abstract][Full Text] [Related]
45. Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement. therapy.
Castorina M; Antuzzi D; Richards SM; Cox GF; Xue Y
Clin Exp Obstet Gynecol; 2015; 42(1):108-13. PubMed ID: 25864295
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
Pérez-López J; Morales-Conejo M; López-Rodríguez M; Hermida-Ameijeiras Á; Moltó-Abad M
Mol Genet Metab; 2017 Jun; 121(2):138-149. PubMed ID: 28410878
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis.
Dornelles AD; Artigalás O; da Silva AA; Ardila DLV; Alegra T; Pereira TV; Vairo FPE; Schwartz IVD
PLoS One; 2017; 12(8):e0184065. PubMed ID: 28859139
[TBL] [Abstract][Full Text] [Related]
48. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression.
Munoz-Rojas MV; Vieira T; Costa R; Fagondes S; John A; Jardim LB; Vedolin LM; Raymundo M; Dickson PI; Kakkis E; Giugliani R
Am J Med Genet A; 2008 Oct; 146A(19):2538-44. PubMed ID: 18792977
[TBL] [Abstract][Full Text] [Related]
49. Laronidase hypersensitivity and desensitization in type I mucopolysaccharidosis: a case report.
Ensina LF; Aranda CS; de Lacerda AE; Camelo-Nunes I; Sole D; Martins AM; Castells M
Pediatr Allergy Immunol; 2014 Aug; 25(5):498-9. PubMed ID: 25313426
[No Abstract] [Full Text] [Related]
50. Enzyme-replacement therapy in mucopolysaccharidosis I.
Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF
N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140
[TBL] [Abstract][Full Text] [Related]
51. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I.
Kakkis E; Lester T; Yang R; Tanaka C; Anand V; Lemontt J; Peinovich M; Passage M
Proc Natl Acad Sci U S A; 2004 Jan; 101(3):829-34. PubMed ID: 14715900
[TBL] [Abstract][Full Text] [Related]
52. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I.
Braunlin EA; Berry JM; Whitley CB
Am J Cardiol; 2006 Aug; 98(3):416-8. PubMed ID: 16860035
[TBL] [Abstract][Full Text] [Related]
53. CASE SERIES OF PATIENTS UNDER BIWEEKLY TREATMENT WITH LARONIDASE: A REPORT OF A SINGLE CENTER EXPERIENCE.
Kyosen SO; Toma L; Nader HB; Braga MC; Pereira VG; Canossa S; Pesquero JB; D'Almeida V; Martins AM
Rev Paul Pediatr; 2019; 37(3):312-317. PubMed ID: 31090850
[TBL] [Abstract][Full Text] [Related]
54. Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme).
Kloska A; Bohdanowicz J; Konopa G; Tylki-Szymńska A; Jakóbkiewicz-Banecka J; Czartoryska B; Liberek A; Wegrzyn A; Wegrzyn G
Am J Med Genet A; 2005 Dec; 139(3):199-203. PubMed ID: 16283671
[TBL] [Abstract][Full Text] [Related]
55. Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study.
Chen AH; Harmatz P; Nestrasil I; Eisengart JB; King KE; Rudser K; Kaizer AM; Svatkova A; Wakumoto A; Le SQ; Madden J; Young S; Zhang H; Polgreen LE; Dickson PI
Mol Genet Metab; 2020 Feb; 129(2):80-90. PubMed ID: 31839529
[TBL] [Abstract][Full Text] [Related]
56. Successful treatment of severe heart failure in an infant with Hurler syndrome.
Hirth A; Berg A; Greve G
J Inherit Metab Dis; 2007 Oct; 30(5):820. PubMed ID: 17768668
[TBL] [Abstract][Full Text] [Related]
57. Apparent allelism of the Hurler, Scheie, and Hurler/Scheie syndromes.
Mueller OT; Shows TB; Opitz JM
Am J Med Genet; 1984 Jul; 18(3):547-56. PubMed ID: 6433708
[TBL] [Abstract][Full Text] [Related]
58. [Enzyme replacement therapy of lysosomal storage diseases].
Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
[TBL] [Abstract][Full Text] [Related]
59. Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience.
Pitz S; Ogun O; Bajbouj M; Arash L; Schulze-Frenking G; Beck M
Arch Ophthalmol; 2007 Oct; 125(10):1353-6. PubMed ID: 17923542
[TBL] [Abstract][Full Text] [Related]
60. Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up.
Jurecka A; Marucha J; Jurkiewicz E; Różdżyńska-Świątkowska A; Tylki-Szymańska A
Pediatr Neurol; 2012 Dec; 47(6):461-5. PubMed ID: 23127271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
